Back to top
more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$68.55 USD

68.55
1,391,330

+1.18 (1.75%)

Updated Sep 18, 2025 04:00 PM ET

After-Market: $68.55 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 245)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

AmerisourceBergen (ABC) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about AmerisourceBergen's (ABC) strength in its World Courier business.

Zacks Equity Research

Catalent's (CTLT) New Tie-Up to Provide Better Patient Access

by Zacks Equity Research

Catalent's (CTLT) latest collaboration is expected to enable it to provide customers access to the TFF technology.

Zacks Equity Research

ResMed's (RMD) SaaS Arm Strength Aids Growth, Supply Woes Stay

by Zacks Equity Research

ResMed's (RMD) growing focus to expand in the high-growth international markets is an added upside.

Zacks Equity Research

Medtronic (MDT) to Gain From New Reimbursement Program for CGM

by Zacks Equity Research

Ontario government's new comprehensive reimbursement program for CGM will enhance access to Medtronic's (MDT) integrated CGM technology for type 1 diabetes patients.

Zacks Equity Research

Here's Why You Should Invest in Bio-Rad (BIO) Stock Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO) on solid recovery in most of its key global markets as well as an uptick in demand for COVID-related products.

Zacks Equity Research

Dexcom's (DXCM) CGM Gets FDA's Breakthrough Device Designation

by Zacks Equity Research

Dexcom's (DXCM) CGM's use in the hospital setting is likely to be more effective in glycemic management and improved patient outcomes.

Zacks Equity Research

Cooper Companies (COO) Q1 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Cooper Companies' (COO) fiscal first-quarter earnings reflect solid segmental performance.

Zacks Equity Research

Bruker (BRKR) to Improve Spatial Biology With New Launch

by Zacks Equity Research

Bruker's (BRKR) acquired company, Canopy Biosciences, introduced its next generation of ChipCytometry instrumentation for spatial biology.

Zacks Equity Research

New Strong Buy Stocks for March 4th

by Zacks Equity Research

BELFB, HSIC, LAD, MRC, and PPC have been added to the Zacks Rank #1 (Strong Buy) List on March 4, 2022.

Zacks Equity Research

Henry Schein (HSIC) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about Henry Schein's (HSIC) favorable dental business trends.

Zacks Equity Research

Veeva (VEEV) Beats on Q4 Earnings, Narrows '23 Revenue View

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal Q4 results reflect impressive performances by both of its segments.

Zacks Equity Research

Bruker (BRKR), Newomics to Co-Market Joint MnESI-MS Platform

by Zacks Equity Research

The maxis II and timsTOF Pro 2 mass spectrometers from Bruker (BRKR) will be marketed with Newomics's MnESI product line.

Zacks Equity Research

Here's Why You Should Retain Haemonetics (HAE) Stock for Now

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE) given strong recovery across businesses and strength in plasma franchise.

Zacks Equity Research

Here's Why You Should Invest in AmerisourceBergen (ABC) Stock

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment.

Zacks Equity Research

Patterson Companies (PDCO) Q3 Earnings Beat, Revenues Lag

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal third-quarter 2022 results benefit from strength in the Dental and Animal Health segments.

Zacks Equity Research

Masimo's (MASI) SedLine Receives FDA's Pediatric Indication

by Zacks Equity Research

The latest FDA clearance for Masimo's (MASI) SedLine is likely to improve brain function monitoring in pediatric patients.

Zacks Equity Research

Henry Schein (HSIC) Expands Data Analytics to Private Practices

by Zacks Equity Research

Henry Schein's (HSIC) introduction of Jarvis Analytics for Private Practices offers practice owners a simple, powerful tool to help improve practice success through data-driven decisions.

Zacks Equity Research

McKesson (MCK) Up 5.1% Since Q3 Earnings: What's Driving It?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) robust segmental performance and raised earnings outlook for fiscal 2022.

Zacks Equity Research

Cooper Companies (COO) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Cooper Companies' (COO) fiscal first-quarter results are likely to reflect segmental strength.

Zacks Equity Research

Alcon (ALC) Surgical Arm Expands, International Growth Slows

by Zacks Equity Research

In Surgical, Alcon (ALC) remains the market leader in presbyopia correcting IOLs on the strength of both PanOptix and Vivity.

Zacks Equity Research

What's in Store for Patterson Companies' (PDCO) Q3 Earnings?

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal third-quarter results are likely to reflect improvement at Animal Health segment.

Zacks Equity Research

Medtronic's (MDT) NuVent Balloon to Strengthen ENT Business

by Zacks Equity Research

Medtronic's (MDT) Nuvent balloons are one-time use devices featuring a flexible balloon section that allows customized placement based on patient anatomy.

Zacks Equity Research

SmileDirectClub (SDC) Q4 Earnings Lag Estimates, Margin Falls

by Zacks Equity Research

SmileDirectClub (SDC) reports lower-than-expected results for the fourth quarter, issues full-year 2022 sales guidance.

Zacks Equity Research

Here's Why You Should Invest In Bruker (BRKR) Stock Now

by Zacks Equity Research

Investors are optimistic about Bruker's (BRKR) better-than-expected revenues and robust segmental performance.

Zacks Equity Research

Inogen (INGN) Stock Surges 16.5% Despite Q4 Earnings Miss

by Zacks Equity Research

Inogen's (INGN) fourth-quarter results benefit from higher revenues across the majority of its geographical segments.